Interleukin-17A Promotes IgE Production in Human B Cells  by Milovanovic, Milena et al.
Interleukin-17A Promotes IgE Production
in Human B Cells
Milena Milovanovic1, Gennadiy Drozdenko1, Christin Weise1, Magda Babina1 and Margitta Worm1
Recently the Th1/Th2 concept has been revised and Th17 cells have been implicated in allergy. Despite clear
correlative evidence, the cellular and molecular basis for the connection between increased IL-17A and IgE in
allergy has not been elucidated. Here we show using flow cytometry that allergic patients have higher numbers
of IL-17Aþ cells compared to nonallergic donors. The selective removal of IL-17Aþ cells from peripheral blood
mononuclear cells of allergic donors after an IL-17A secretion assay reduces IgE levels, whereas re-addition of
recombinant IL-17A restores it, as measured by ELISA, showing their important functional implication for IgE
production. In addition, IL-17A directly promotes the differentiation of IgE-secreting cells and IgE production
upon anti-CD40/IL-4 costimulation, as shown by enzyme-linked immunospot technique and ELISA. IL-17A
triggers rapid degradation of IkBa and subsequent translocation of NF-kB into the B-cell nucleus, followed by
transcription of epsilon germ-line, activation-induced cytidine deaminase, and IFN regulatory factor 4, as
analyzed by flow cytometry, western blot, and quantitative real-time RT-PCR, respectively. Our study shows that
IL-17Aþ cells promote IgE production and that IL-17A exerts its pro-allergic effect directly at the level of B cells.
Therefore, IL-17A might be a target for the treatment of IgE-dependent diseases, including atopic dermatitis.
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INTRODUCTION
The key component of type I allergy is IgE directed against
innocuous environmental antigens (Poulsen and Hummel-
shoj, 2007). IgE production proceeds in three tightly
regulated stages: germ-line gene transcription, class switch
recombination (CSR), and plasma cell differentiation (Gould
and Sutton, 2008). Epsilon germ-line transcription (eGLT) is a
prerequisite for the initiation of IgE CSR, by marking the sites
for enzyme activation induced (cytidine) deaminase (AID),
responsible for the DNA breaks (Geha et al., 2003). At least
two independent signals are required for IgE CSR and IgE
plasma cell differentiation (Poulsen and Hummelshoj, 2007).
The classical pathway involves IL-4 (or IL-13) and CD40L,
operating through simultaneous activation of the STAT6 and
NF-kB pathway, respectively. Various other cytokines influ-
ence IgE production by providing promoting or inhibitory
signals. However, none of the supplementary factors can
normally replace either of the two ‘‘dominant’’ signals
required, with the exceptions of BAFF, APRIL, C4 binding
protein, and corticosteroids under certain circumstances
(Geha et al., 2003). In addition, IL-21 was also recently
described to enhance IgE production in humans as reviewed
by Konforte et al. (2009).
In contrast to their protective role in host defense against
extracellular organisms, Th17 cells promote tissue destruc-
tion in autoimmune diseases (Boniface et al., 2008; Pernis,
2009). Their role in allergy is less well defined, although
emerging evidence has associated IL-17A and allergic
diseases as reviewed by Tesmer et al. (2008) and Louten
et al. (2009). To our knowledge, previously unreported
models revise the role of Th1/Th2 and highlight the
interaction of Th17 with Th2 cells, keratinocytes, and
fibroblasts in the pathogenesis of atopic dermatitis (AD), but
the exact role of IL-17A in AD is controversial. Further
indication for a pro-allergic, IgE-promoting function of IL-17A
comes from the analysis of the IL-17A/ mice (Nakae et al.,
2002; He et al., 2007; Wakashin et al., 2008). In particular,
ovalbumin-sensitized IL-17A/ mice have reductions speci-
fically in IgG1 and, most profoundly, IgE levels compared to
those in IL-17Aþ /þ mice. Moreover, Th17-mediated auto-
immune gastritis is accompanied by high serum IgE levels
(Stummvoll et al., 2008). However, the mechanisms behind
the changes in IgE production in the context of IL-17A hyper-
or hypoexpression have remained unexplored so far.
Interestingly, IL-17A promotes B-cell activity and function
in germinal centers of BXD2 mice, suggesting that B cells
might be a substantial target for IL-17A (Hsu et al., 2008).
A most recent report showed that B cells display increased
survival, proliferation, and differentiation into plasma cells
upon BAFF/IL-17A-mediated costimulation (Doreau et al.,
2009).
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On the basis of the above evidence, we hypothesized that
IL-17A has a role in IgE production by B cells. Therefore, we
studied the contribution of Th17 cells to the maintenance of
elevated IgE levels encountered in allergic subjects and
analyzed whether IL-17A acted directly on B cells to induce
IgE CSR and the differentiation of IgE-producing cells.
RESULTS
Allergic patients have increased numbers of IL-17Aþ cells
Since increased levels of IL-17A have been found locally and
systemically in patients suffering from asthma and AD (Koga
et al., 2008), we tested whether allergic patients may display
increased amounts of Th17 cells. Nonallergic and allergic
donors are characterized in Table 1. After a whole-blood
assay with Staphylococcal enterotoxin B/anti-CD28 stimula-
tion, followed by intracellular staining, flow cytometric
analysis of IL-17A, CD4, and CD154 was performed. Th17
cells made up for 0.5–4.7% of the CD4þCD154þ popula-
tion (activated T-helper cells) in nonallergic individuals. In
allergic donors, this proportion increased to 1–13.7%
(elevated by 1.5-fold) (Figure 1a). Six patients (two men and
four women) with the highest numbers of IL-17Aþ cells were
all asthmatic, between 26 and 40 years of age. There was no
difference in the percentages of activated T-helper cells
between allergic and nonallergic donors (data not shown),
excluding that the higher numbers found in allergic donors
were the result of their general increase.
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Figure 1. Allergic patients have increased numbers of IL-17Aþ cells, which support IgE production. (a) Allergic patients have higher numbers of IL-17Aþ cells
than nonallergic donors. After a whole-blood assay, cells were subjected to intracellular staining of IL-17A, CD154, and CD4. Data are shown as single values
with median. *Po0.05; Mann–Whitney U-test. (b) Peripheral blood mononuclear cells (PBMCs) before and after separation of IL-17A-producing cells.
(c) IL-17Aþ cells promote IgE production in allergic patients. IgE production was compared before and after the removal of IL-17A-producing cells. In addition,
IL-17A or IL-22 was added to cultures of PBMCs without IL-17Aþ cells. Data are shown as mean±SEM. *Po0.05; Wilcoxon signed-rank test; n¼ 6–14.
(d) IL-17A promotes IgE production in allergic patients. PBMCs were cultured with/without an anti-IL-17A-blocking antibody. Data are show as mean±SEM;
n¼ 4–5. (e) IFN-gþ cells do not promote IgE production in allergic patients. IgE production was compared before and after the removal of IFN-g-producing cells.
Data are shown as mean±SEM; n¼5.
Table 1. Characterization of nonallergic and allergic
donors
Nonallergic donors Allergic patients
n 16 23
Female/male 11/5 15/8
Age (years)1 30.5 (23–37) 29 (23–51)
Total plasma IgE (ngml1)1 23.52 (0.70–191.40) 426.60 (0.70–2492.10)
Asthma 0 13
Allergic rhinitis 0 13
Atopic dermatitis 0 3
1Median (range).
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IL-17A-producing cells support IgE production in allergic
donors
We investigated whether the Th17 population contributes to
the elevated IgE production in allergic patients with AD. It is
known that B cells from allergic patients spontaneously
produce IgE in vitro (Turner et al., 1987). Peripheral blood
mononuclear cells (PBMCs; stimulated with anti-CD2/anti-
CD3/anti-CD28 for 24 hours) from which the IL-17Aþ
population had been removed (or not) by means of a
secretion assay were analyzed for IgE production after
72 hours of culture. Upon the selective removal of
IL-17Aþ cells (a representative example is given in Figure
1b), IgE production declined to 25.86±7.26% (Figure 1c;
compare column 1 to column 2). To elucidate whether the
IgE-promoting effect of Th17 cells was due to the production
of IL-17A itself or mediated by other factors, we re-added
recombinant IL-17A to Th17-depleted cultures, which
completely restored IgE levels (Figure 1c; compare column
2 to column 3). Because Th17 also produce IL-22, we re-
added IL-22 to Th17-depleted cultures as well, which could
not restore IgE production (Figure 1c; compare column 2 to
column 4). To exclude an influence of the separation method,
we performed an IFN-g secretion assay and depleted IFN-g-
producing cells from PBMCs. There was no significant
difference in IgE production between the total PBMC
population and PBMCs without IFN-gþ cells (Figure 1e).
In a second approach, an IL-17A-blocking antibody was
added to resting PBMCs obtained from donors with AD. Anti-
IL-17A was as effective as the removal of IL-17Aþ cells (IgE
production decreased to 42±12.5, Figure 1d), confirming
that IL-17A was involved in IgE production. The specificity
was proven by the use of an isotype control antibody.
Interestingly, the blocking of IL-17A did not affect the
spontaneous production of other Ig isotypes (Figure 2).
Due to the limiting cell numbers, the experiments shown in
Figure 1c and d could not be performed with cells from the
same individuals. However, the same criteria as listed in
Table 1 were used for their selection.
IL-17A directly promotes IgE production and increases the
number of IgE-producing cells
To investigate the direct impact of IL-17A on IgE production,
we stimulated purified B cells with anti-CD40/IL-4 in the
presence of IL-17A at different concentrations for 10 days. IgE
production of unstimulated B cells was below the detection
limit (o20 pgml1), as expected. IL-17A increased IgE
production of IL-4/anti-CD40-stimulated cells in a dose-
dependent manner (Figure 3a). The most effective concentration
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Figure 2. Blocking of IL-17A has no impact on IgM, IgA, or IgG production.
Peripheral blood mononuclear cells (PBMCs) were cultured with/without an
anti-IL-17A-blocking antibody. IgM, IgA, and IgG levels were determined in
supernatants by ELISA. Data are shown relative to unstimulated PBMC
samples as mean±SEM; n¼ 4–5.
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Figure 3. IL-17A provides IgE production in B cells and increases the number of IgE-producing cells. (a) IL-17A dose-dependently induces IgE production.
B cells were stimulated with anti-CD40/IL-4 and costimulated with IL-17A for 10 days. IgE was determined in supernatants by ELISA. The data represent
single values. *Po0.05; Wilcoxon paired test; n¼5–6. (b) IL-17A contributes to the generation of IgE-secreting cells. B cells were stimulated with anti-CD40/IL-4
with/without IL-17A for 6 days. Number of antibody-secreting cells was determined by enzyme-linked immunospot (ELISpot) technique. The data show
single values from five donors. The ELISpot wells are representative and are from one selected donor.
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was 10ngml1 of IL-17A and therefore this concentration was
used for the subsequent experiments. IL-17A alone did not
induce IgE secretion by B cells (data not shown).
To delineate whether the IgE-promoting effect of IL-17A
was isotype specific, we analyzed the other Ig isotypes. There
was no significant change in IgM, IgA, and IgG production
upon IL-17A/anti-CD40/IL-4 stimulation, although a ten-
dency toward increased levels of IgM and IgG isotypes was
noted (data not shown).
An enzyme-linked immunospot assay was performed to
verify whether the enhanced amount of IgE in supernatants
was due to a higher number of plasma-like cells. The addition
of IL-17A to anti-CD40/IL-4-stimulated B cells indeed
increased the numbers of IgE plasma-like cells. Although
the level of increase was donor dependent, the number of IgE
secreting cells increased in all donors upon IL-17A costimu-
lation (Figure 3b). Together the data indicate that IL-17A
supports the differentiation of B cells into IgE plasma cells.
IL-17A induces IgE CSR
We addressed the effect of IL-17A on the expression of key
factors required for IgE CSR. Anti-CD40/IL-4 stimulation of B
cells, used as positive control, induced eGLT, AID, and IFN
regulatory factor 4 mRNA expression, as expected.
Interestingly, the stimulation with IL-17A alone led to a
significant increase in eGLT, AID, and IFN regulatory factor 4
mRNA expression (Figure 4) in the same range as anti-CD40/
IL-4. This implies that IL-17A may have a similar biological
effect as anti-CD40/IL-4 on the molecular events preceding
CSR to IgE.
IL-17A induces IjBa degradation and p50 translocation into the
nucleus of B cells
The most important downstream target of IL-17A is NF-kB
(Gaffen et al., 2006; Huang et al., 2007) and NF-kB itself is
crucial for IgE CSR (Geha et al., 2003).
To explore whether IL-17R triggering leads to NF-kB
activation in B cells, we analyzed IkBa by flow cytometry.
IkBa degradation was initiated by IL-17R stimulation
(Figure 5), achieving the maximal response 15minutes after
IL-17A addition (mean fluorescence intensity decreased to
77±14%, Figure 5a). IkBa decreased to 75±20% upon anti-
CD40 stimulation (used as positive control), but after
45minutes. Thus, our data show that IL-17A elicits IkBa
degradation more rapidly than anti-CD40.
The study of B-cell subsets revealed that IL-17A exerts
comparable effects on IkBa degradation in both naive (gated
on CD27) and memory B cells (gated on CD27þ ) (data not
shown).
To investigate whether the increased IkBa degradation by
IL-17A was accompanied by p50 translocation, we analyzed
its nuclear translocation by western blot. Stimulation with
anti-CD40 (positive control) caused robust translocation of
p50 into the nucleus (Figure 5c). The same pattern was
observed with IL-17A, which resulted in rapid and prominent
p50 shuttling into the nucleus (Figure 5c). Taken together,
IL-17A (similar to anti-CD40) induces IkBa degradation,
followed by profound translocation of p50 into the B-cell
nucleus.
DISCUSSION
Our data show that IL-17A exerts a pro-allergic action on B
cells by triggering IgE. We show that Th17 cells are increased
in allergic subjects and that these cells contribute to IgE
production by PBMCs. Because Th17 cells produce an array
of mediators other than IL-17A, it was important to assess
whether IL-17A directly induces IgE production. We show
that this is indeed the case. Th17-depleted cultures showed a
strongly reduced IgE response that was restored by exogenous
IL-17A, but not by IL-22. Furthermore Th17 removal was
mimicked by the addition of blocking anti-IL-17A antibody.
By using highly purified B cells and recombinant IL-17A, we
finally established that IL-17A enhances IgE production
and the differentiation of IgE plasma cells by direct action
on B cells.
IL-17A effects are mediated through IL-17A receptor
complexes composed of at least two IL-17RA subunits and
at least one IL-17RC subunit (Shen and Gaffen, 2008). The
major signaling intermediates include Act1/TAK1/TRAF6,
coordinating NF-kB, and JAK1-associated phosphatidylinosi-
tol-3-kinase signaling (Huang et al., 2007). We show that B-
cell stimulation with IL-17A leads to a rapid degradation of
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Figure 4. IL-17A induces IgE class switch recombination. IL-17A induces (a) epsilon germ-line transcript (eGLT), (b) activation-induced (cytidine) deaminase
(AID), and (c) IFN regulatory factor 4 (IRF4) mRNA expression. B cells were stimulated with IL-17A for 72 hours. Anti-CD40/IL-4 stimulation was used as
positive control. The measurement was performed using quantitative PCR. The data are shown as fold expression of anti-CD40/IL-4-stimulated samples and are
shown as mean±SEM. *Po0.05; Wilcoxon signed-rank test; n¼ 4–5. ND¼ not detectable.
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IkBa to a comparable degree as with anti-CD40. This is
followed by p50 translocation (and to a lesser degree p65,
data not shown) into the B-cell nucleus. The importance of
NF-kB signaling for CSR is indisputable. NF-kB binding sites
have been identified in the promoters of molecules required
for CSR (Geha et al., 2003). Functional NF-kB binding sites
are found in the promoters of eGLT, AID, and IFN regulatory
factor 4, and their importance was shown in p50 knockout
mice, failing to upregulate AID and eGLT (Messner et al.,
1997; Geha et al., 2003).
In general, IgE CSR and plasma cell differentiation require
the simultaneous triggering of the CD40 and the IL-4R
(Poulsen and Hummelshoj, 2007). The concurrent activation
of NF-kB and STAT6 initiates a cascade culminating in the
AID and eGLT transcription. We show here that IL-17A
directly induces eGLT and AID. Thus, the concomitant IL-
17A stimulation increases IgE CSR in purified B cells and
augments the generation of IgE plasma cells.
However, IgE production can be maintained even in the
absence of Th17 cells, as seen in the hyper IgE syndrome.
Although this seems to be contradictory, a recent report
showed the crucial role of STAT3 signaling for memory B-cell
formation and the differentiation of germinal center B cells
into plasma cells, by acting in a B-cell intrinsic manner
(Avery et al., 2010). B cells with STAT3 mutations exhibit less
Bcl-6. As Bcl-6 is a negative regulator of IL-4-induced STAT6
signaling and consequently eGLT expression (Harris et al.,
1999), this might explain why patients suffering from hyper
IgE syndrome have increased IgE levels. Taken together,
STAT3 mutations result in both a dysregulation of T cell (Ma
et al., 2008) and B-cell intrinsic functions. In the context of
allergy, a clear supportive role of Th17 cells for IgE
production could be uncovered here, providing the mole-
cular link between enhanced IL-17A activity and increased
IgE levels found in allergic subjects.
IL-17A is a cofactor contributing to the enhanced IgE
production in allergic individuals, but it does not clearly act
on its own. This is also emphasized by the fact that enhanced
Th17 function, encountered in various inflammatory dis-
eases, does not predisposes per se in enhanced IgE
production, e.g. in multiple sclerosis, Crohns’s disease,
arthritis, and also psoriasis (Louten et al., 2009). Interestingly,
increased IgE levels have been reported in some patients
suffering from psoriasis (Negosanti et al., 1981) and our data
may explain these previous observations. The fact that not all
patients develop increased IgE may depend on the genetic
background as well (Wilsmann-Theis et al., 2008). Under
such circumstances, IgE production is not promoted
possibly because other stimulatory cytokines (such as IL-4
or IL-13) are not present in sufficient quantities. Our assays
rather mimic the conditions encountered in allergic subjects,
either by using PBMCs derived from AD patients, which
spontaneously produce high IgE levels (Figure 1), or by
simulating the T-cell help of a Th2 cell by addition of anti-
CD40/IL-4. In a Th2-like environment, IL-17A clearly
promotes IgE production.
The role of IL-17A in psoriasis is well established (Louten
et al., 2009), whereas its role in AD has been controversially
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discussed. It is currently believed that IL-17A is an enhancer
rather than an immune polarizer in AD and that it is primarily
associated with acute rather than chronic stages of the
disease (Koga et al., 2008). Epicutaneous sensitization
through the compromised skin barrier induces a local and
systemic Th17 response that accounts for the symptoms of
asthma, frequently co-occurring in AD patients (He et al.,
2007). Our finding that IL-17A potentiates IgE production
may contribute to the allergic responses in these patients.
Moreover, the activation of dendritic cells by cross-linking of
IgE molecules, leads to polarization of naive T cells into Th2
cells and their cytokine secretion, which are of major
importance for the acute AD (Avgerinou et al., 2008). It is
also discussed that Th2-derived IL-4 suppresses IL-17A
secretion during acute AD (Nograles et al., 2009). Further-
more, during the acute AD recruited Th17 cells can activate
eosinophils, by increasing their IL-8 and CXCL1 production
(Louten et al., 2009). Conversely, the chronic AD phase is
dominated by Th1 cytokines and IL-22, but not by IL-17A
(Toda et al., 2003; Guttman-Yassky et al., 2008; Koga et al.,
2008). It was recently established that T cells can indepen-
dently express IL-22 (a Th17-related cytokine), and that these
‘‘T22’’ cells may be important for AD severity (Nograles
et al., 2009).
Taken together, our data imply a biological relevance of
IL-17A for IgE production. Although future studies will have
to assess in detail whether interference with the exaggerated
Th17 activity in allergic patients might be a feasible treatment
option, our findings provide a first hint that IL-17A may turn
out a significant target for the prevention and/or therapy of
allergic diseases.
MATERIAL AND METHODS
Cell preparation and cell culture
PBMCs were separated from heparinized blood obtained
from nonallergic donors, if not stated otherwise, by density
gradient centrifugation using Ficoll (PAA, Pasching, Austria).
Nonallergic and allergic donors are characterized in Table 1.
After density gradient centrifugation using Ficoll and two
washing steps with phosphate-buffered saline, cells were
labeled with anti-CD19 beads, washed, and positively
selected to 499% purity by magnetic sorting (Miltenyi,
Bergisch Gladbach, Germany) as described previously
(Milovanovic et al., 2009). B cells or PBMCs (106 per ml)
were cultured in flat-bottomed 48-well plates in Roswell’s
Park Memorial Institute 1640 medium supplemented with
10% heat-inactivated fetal calf serum, glutamine (2mM),
penicillin (100Uml1), and streptomycin (100mgml1) (all
from Biochrom, Berlin, Germany). Cultures were carried out
at 37 1C in humidified air and 5% CO2. The study was
approved by the ethics committee of the Charite´ Universi-
ta¨tsmedizin, was conducted according to the Declaration of
Helsinki Principles, and all patients gave written informed
consent.
Reagents and antibodies
Recombinant human IL-17A and IL-4 (5 ngml1, both from
ImmunoTools, Friesoythe, Germany), the anti-CD40 mAb
(100 ngml1; DRFZ, Berlin, Germany), IL-22 (10 ngml1),
the neutralizing anti-IL-17A mAb (1mgml1), and isotype
control mouse IgG2B (all from R&D Systems, Wiesbaden,
Germany) were used. The purity of recombinant human IL-
17A is 498.0% as determined by RP-HPLC and SDS-PAGE
silver stained gel, as stated by the manufacturer. Fluoro-
chrome-coupled anti-IL-17A and anti-CD27 were from
eBioscience (San Diego, CA); anti-CD19, anti-CD3, and
anti-CD4 were from BD PharMingen (San Diego, CA); and
anti-IkBa was from Cell Signaling Technology (Boston, MA).
Dead cells were excluded using propidium iodide staining
(Sigma-Aldrich, Steinheim, Germany).
Flow cytometric analyses of IL-17A-expressing T cells
Heparinized blood was stimulated using Staphylococcal
enterotoxin B (Sigma-Aldrich) and anti-CD28 (BD PharMin-
gen) for 6 hours. Brefeldin A (Sigma-Aldrich) was added
2 hours after beginning. Cells were treated with lysing
solution (BD PharMingen), followed by Perm II solution
(BD PharMingen). Intracellular staining was performed with
anti-human IL-17A, anti-CD154, and anti-CD4. The analysis
was performed using flow cytometer (FACSCalibur; Becton
Dickinson, Heidelberg, Germany) and FlowJo 7.2.2 (Tree
Star, Ashland, OR).
Detection and separation of IL-17A- and IFN-c-producing cells
PBMCs were stimulated with a T-cell activation/expansion kit
(anti-CD2, anti-CD3, anti-CD28; Miltenyi) for 24 hours. The
secretion assay was performed using IL-17A or IFN-g
secretion assay kits (both from Miltenyi) under the manu-
facturers’ instructions. Afterward, the cells were cultured for
72 hours and IgE production was measured.
ELISA
IgE levels were determined by ELISA as previously described
(Heine et al., 2009). For IgE detection, clones HP6061 and
HP6029 (SouthernBiotech, Birmingham, AL) were used. The
matched antibody pairs for IgA, IgG, and IgM ELISA (anti-IgA,
anti-IgG, and anti-IgM) were purchased from Dianova
(Hamburg, Germany). Immunoplates (Nunc, Wiesbaden,
Germany) were coated overnight at 4 1C with the primary
antibodies. After blocking of unspecific binding, supernatants
and standards were incubated for 2 hours. The second
alkaline phosphatase-conjugated anti-Ig antibody was added
for 1.5 hours. Because the secondary mouse anti-human IgE
antibody was biotinylated (HP6029), another hour of
incubation with alkaline phosphatase-conjugated streptavi-
din (Zymed, San Francisco, CA) was performed. After the
final reaction with phosphatase substrate (Sigma-Aldrich),
plates were read in a microplate ELISA reader (Dynatech,
Chantilly, VA) at 405 nm and the amount of Ig was
calculated according to the standard curve. Diluted human
serum of an atopic individual served as standard curve
preparation.
Enzyme-linked immunospot technique
MultiScreen High-Protein-Binding Immibilion-P Membrane
plates (Millipore, Schwalbach, Germany) were coated with
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mouse anti-human IgE (HP6061). B cells (3106) were used
for each stimulation. After 6 days of culture, each sample
was serially diluted (1:3 into seven wells) on the precoated
plate and incubated at 37 1C overnight. Detection was
performed with biotin-conjugated antibody mouse anti-
human IgE antibody (HP6029). The reaction was developed
with streptavidin-horseradish peroxidase (R&D Systems) and
peroxidase substrate 33-amino-9-ethyl-carbazole/n,n-dimethyl-
formamide (Sigma-Aldrich).
Antibody-secreting cells, appearing as red spots, were
analyzed with the CTL ImmunoSpot S4 Analyzer (C.T.L.
Cellular Technology, Cleveland, OH).
RNA extraction and PCR
RNA isolation of single-cell suspensions and synthesis of
cDNA were performed according to the manufacturers’
instructions using RNA isolation kit Nucleospin RNA II
(Macherey-Nagel, Dueren, Germany) and TaqMan Reverse
Transcription Reagent (Applied Biosystems, Darmstadt, Ger-
many). Gene expression was analyzed using real-time
quantitative PCR. The primers (TIB Molbiol, Berlin, Germany)
were applied at a hybridization temperature of 65 1C at
concentration of 500 nM. Primers for HPRT were sense
TggCTTATATCCAACACTTCgTg and antisense ATCAgACTg
AAgAgCTATTgTAATgACCA; for eGLT sense gACgggCCACA
CCATCCACAggCACCAAATggACgAC and antisense CAggAC
gACTgTAAgATCTTCACg; for AID sense AgAggCgTgACAgTg
CTACA and antisense ATgTAgCggAggAAgAgCAA; and for
IFN regulatory factor 4 sense CCAggTgACTCTATgCTTTgg
and antisense CTTTgCgCTCATAACgTCAg.
Flow cytometric analysis of IjBa degradation
After fixation with 4% paraformaldehyde for 10minutes at
37 1C, permeabilizing with Perm II solution (BD PharMingen)
for 30minutes at 4 1C, cells were stained with FITC-coupled
anti-IkBa (Cell Signaling Technology), anti-CD19 (BD Phar-
Mingen), and anti-CD27 (eBioscience), and analyzed using
flow cytometery.
Protein isolation and western blotting
NE-PER extraction reagent (Pierce, Rockford, IL) containing a
protease inhibitor cocktail (Roche, Penzberg, Germany) was
used for protein extract preparation. After nuclear extracts
separation on tris-glycine SDS-PAGE, proteins were trans-
ferred to polyvinylidene difluoride membrane (Amersham
Biosciences, Freiburg, Germany). Membranes were incu-
bated with anti-human p50 (Santa Cruz Biotechnology,
Heidelberg, Germany) or anti-human nucleolin (used as
nucleus loading control; Sigma-Aldrich). After incubation
with HRP-conjugated goat anti-rabbit IgG (Santa Cruz
Biotechnology), antigen detection was performed with the
chemiluminescent detection system ECL Plus (Amersham
Biosciences).
Statistics
Statistical calculations were performed using GraphPad Prism
(La Jolla, CA). Wilcoxon signed-rank test for nonparametrical,
paired data was carried out to analyze the within-group
changes. The two-tailed Mann–Whitney test was used to
compare results between groups.
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